Mortality, hospital length of stay and recurrent bloodstream infections associated with extended-spectrum beta-lactamase producing Escherichia coli (ESBL-Ec) in a low prevalence region: A 20-year population-based large cohort study

The incidence of Escherichia coli bloodstream infection (BSI) has been on the rise. This can be attributed to several factors such as population growth, ageing and increased comorbidity in the global population. [1,2] This phenomenon is exacerbated by the expansion of E. coli producing extended-spectrum beta-lactamase (ESBL-Ec), which are multidrug-resistant and compromise empirical treatment. The expansion of ESBL-Ec globally is well-evidenced in community settings, attributed in part to a successful clonal group, ST131, that is commonly associated with blaCTX-M carriage.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research